- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
"Not So Different": What's Next for Drug Pricing After Withdrawal of the Rebate Rule?
In July, the Trump administration withdrew its proposal to block rebates and discounts given by drug makers to pharmacy benefit managers, Part D plans, and Medicaid managed care organizations. Withdrawal of the rule was a discouraging development for many physicians who hoped that the proposal could give relief to their patients at the pharmacy counter. This week on the podcast, we’re speaking to one such physician, Madelaine Feldman, MD.
In July, the Trump administration withdrew its proposal to block rebates and discounts given by drug makers to pharmacy benefit managers, Part D plans, and Medicaid managed care organizations. HHS previously said that the rule would counteract incentives behind higher list prices.
Withdrawal of the rule was a discouraging development for many physicians who hoped that the proposal could give relief to their patients at the pharmacy counter. This week on the podcast, we’re speaking to one such physician, Madelaine Feldman, MD.
Feldman is a rheumatologist in private practice with The Rheumatology Group in New Orleans, Louisiana. She is president of the Coalition of State Rheumatology Organizations, which is a founding member of the Alliance for Transparent and Affordable Prescriptions. She is also chair of the Alliance for Safe Biologic Medicines and a past member of the American College of Rheumatology’s insurance subcommittee.
Read more about the withdrawn rule here, and read more about the Senate Finance Committee's bill here.
Newsletter
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.
Escaping the Void: All Things Biosimilars With Craig & G
August 6th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
